News

An evaluation conducted by the appropriate specialist is the most important factor in diagnosing and managing this patient population.

To control pain and inflammation most effectively and responsibly for our cataract surgery patients, we must not only use the appropriate drugs but also ensure they are delivered in the most beneficial manner. We should be mindful of the implications of our pharmaceutical strategies and their impact on our patients.

ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

Striving to improve outcomes is important because of the negative effect of astigmatism on patients’ vision postoperatively.

AGTC-501 is a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa.

Marking Glaucoma Awareness Month this month, Bausch + Lomb and the Glaucoma Research Foundation have released key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma.

The acquisition brings the Hydrus Microstent into Alcon’s global surgical portfolio. The company will leverage its global footprint and leadership in ophthalmology to drive future growth, bringing the device to more patients worldwide.

According to the company, the iScan80 is a high-speed OCT system ideal for practices seeking an affordable and versatile OCT system.

According to the company, 4D-150 is a dual-transgene, intravitreal gene therapy designed to inhibit four distinct angiogenic factors to prevent angiogenesis and reduce vascular permeability for the treatment of wet AMD.

The gift will target expansion of the clinical space at Shiley Eye Institute, which opened 30 years ago with foundational support from the couple. It is part of a $27 million renovation and improvement project being undertaken by UC San Diego.

Team at University of California, Irvine provides an understanding of the mechanisms underlying the pathologies of certain gene mutations.

Investigators say study validates the importance of history-based donor screening while also demonstrating that postmortem PCR testing as a criterion for procurement and subsequent use of tissue isn’t necessary.

The novel gene therapy product candidate is being developed as a potential single intravitreal administration for blue cone monochromacy by delivering a functional copy of the OPN1LW gene.

Awards will be presented at the 11th Annual Focus on Eye Health National Summit, to be held virtually on July 13-14.

The rate of adverse events was low in this higher risk, difficult-to-manage population of special-needs children, noted Margaret Reynolds, MD.

Electro-optical tech producer Gentex brings experience in automotive industry to healthcare, streamlining and enhancing production for eSight’s assistive medical devices.

The new procedure eliminates the need for scleral flaps by positioning the T-shaped IOL haptics in the scleral wall.

The grant will provide Steven DeVries, MD, PhD, the opportunity to travel to Kyoto, Japan and learn from scientists at Ritsumeikan University about the process of growing 3D retinal organoids from stem cells, a technique first developed in Japan.

Clear communication, on-call services, and listening to your patients may keep them from expensive and often unnecessary emergency room visits.

According to investigators, the elevated risk is associated with cataract type, case complexity, and history of DME/PDR.

Consecutive intravitreal dexamethasone treatments may be beneficial for patients with DME patients who had undergone a previous vitrectomy.

Delayed presentations and acute shortage of donor corneal tissues for emergency keratoplasty are among reasons given for adverse outcome.

Researchers have found that study participants with healthy eyes and no history of AMD had thinner retinas if they carried the genes that put them at risk.

For 72 straight hours, the study volunteer lay in a bed at UT Southwestern, the monotony broken only at night when researchers placed his lower body in a sealed, vacuum-equipped sleeping bag to pull down body fluids that naturally flowed into his head while supine.

The improvement became evident during an average time of 6 months.

In light of another unprecedented year filled with technological advancements and pivots as a result of the pandemic, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.

The approach seems to provide high levels of spectacle independence and patients' satisfaction, with limited complications associated.